Your browser is no longer supported. Please, upgrade your browser.
SYRS Syros Pharmaceuticals, Inc. daily Stock Chart
SYRS [NASD]
Syros Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.79 Insider Own2.00% Shs Outstand43.92M Perf Week3.05%
Market Cap451.61M Forward P/E- EPS next Y-1.64 Insider Trans-2.27% Shs Float41.56M Perf Month15.72%
Income-76.20M PEG- EPS next Q-0.40 Inst Own88.70% Short Float6.53% Perf Quarter67.35%
Sales3.90M P/S115.80 EPS this Y1.70% Inst Trans7.72% Short Ratio8.04 Perf Half Y106.54%
Book/sh1.74 P/B5.63 EPS next Y1.20% ROA-50.20% Target Price12.57 Perf Year55.64%
Cash/sh2.64 P/C3.70 EPS next 5Y- ROE-84.20% 52W Range4.26 - 11.93 Perf YTD41.68%
Dividend- P/FCF- EPS past 5Y-22.20% ROI-97.20% 52W High-17.94% Beta1.59
Dividend %- Quick Ratio6.30 Sales past 5Y- Gross Margin- 52W Low129.81% ATR0.75
Employees83 Current Ratio6.30 Sales Q/Q380.00% Oper. Margin- RSI (14)58.16 Volatility6.54% 9.14%
OptionableYes Debt/Eq0.27 EPS Q/Q19.60% Profit Margin- Rel Volume0.77 Prev Close9.51
ShortableYes LT Debt/Eq0.26 EarningsMay 07 BMO Payout- Avg Volume337.65K Price9.79
Recom2.10 SMA205.68% SMA5023.36% SMA20029.40% Volume258,650 Change2.94%
Jan-17-20Downgrade Wedbush Outperform → Neutral
Mar-08-19Resumed JMP Securities Mkt Outperform $18
Feb-14-19Resumed Oppenheimer Outperform $13
Nov-05-18Upgrade ROTH Capital Neutral → Buy
Mar-13-18Reiterated Wedbush Outperform $11 → $13
Oct-31-17Resumed Piper Jaffray Overweight $30
Oct-23-17Initiated ROTH Capital Neutral $15
Aug-10-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
May-29-20 08:01AM  Syros Presents New Preclinical Data on SY-5609 at 2020 ASCO Virtual Scientific Program Business Wire
May-28-20 08:00AM  Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity PR Newswire
May-19-20 07:22AM  Top Ranked Momentum Stocks to Buy for May 19th Zacks -7.61%
May-13-20 05:01PM  Syros to Present New Preclinical Data on SY-5609 at ASCO Virtual Scientific Program Business Wire -9.00%
May-12-20 10:32AM  Industry Analysts Just Upgraded Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Revenue Forecasts By 20% Simply Wall St. -9.43%
May-08-20 02:31PM  Syros Pharmaceuticals, Inc.(SYRS) Q1 2020 Earnings Call Transcript Motley Fool +10.60%
May-07-20 10:05AM  Syros Pharmaceuticals Inc (SYRS) Reports Q1 Loss, Tops Revenue Estimates Zacks
08:08AM  Recap: Syros Pharmaceuticals Q1 Earnings Benzinga
07:30AM  Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones Business Wire
May-06-20 10:01AM  Volatility 101: Should Syros Pharmaceuticals (NASDAQ:SYRS) Shares Have Dropped 37%? Simply Wall St.
Apr-30-20 08:30AM  Syros to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020 Business Wire
Apr-29-20 12:34PM  Will Syros Pharmaceuticals, Inc. (SYRS) Report Negative Q1 Earnings? What You Should Know Zacks
Apr-07-20 09:30AM  Billionaire Steven Cohen Picks up These 2 Stocks on the Dip TipRanks
Mar-26-20 10:16AM  Edited Transcript of SYRS earnings conference call or presentation 5-Mar-20 1:30pm GMT Thomson Reuters StreetEvents +6.18%
Mar-22-20 10:27AM  Does Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Have A High Beta? Simply Wall St.
Mar-05-20 08:45AM  Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates Zacks
07:30AM  Syros Reports Fourth Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones Business Wire
Feb-27-20 12:30PM  Syros Pharmaceuticals, Inc. (SYRS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
08:00AM  Syros to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020 Business Wire
Feb-24-20 08:00AM  Syros to Present at Upcoming Investor Conferences in March Business Wire -8.98%
Feb-13-20 08:00AM  Syros Announces $60 Million Loan Facility with Oxford Finance LLC Business Wire
Feb-06-20 02:03PM  Here's Why We're Watching Syros Pharmaceuticals's (NASDAQ:SYRS) Cash Burn Situation Simply Wall St.
Jan-29-20 08:31AM  Syros Presents New Preclinical Data Highlighting Its Leadership in CDK Inhibition to Discover and Develop New Medicines for Difficult-to-Treat Cancers Business Wire
Jan-28-20 08:31AM  Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-5609, Its Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Select Solid Tumors Business Wire
Jan-15-20 08:29AM  Can The Uptrend Continue for Syros Pharmaceuticals? Zacks
Jan-12-20 09:00AM  Syros Announces Strategic Priorities and Expected Milestones Business Wire
Dec-20-19 11:40AM  Is Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Paid At A Competitive Rate? Simply Wall St. +13.11%
08:01AM  Syros Announces Appointment of Mark Alles to Its Board of Directors Business Wire
Dec-19-19 05:20PM  Fresh off first sickle cell drug approval, Global Blood strikes new deals American City Business Journals +15.74%
08:00AM  Flagship Unveils Newest Pioneering Platform: Ring Therapeutics PR Newswire
Dec-18-19 07:51AM  Global Blood Therapeutics and Syros Pharmaceuticals partner for sickle cell therapies MarketWatch +16.23%
07:15AM  GBT Secures $150 Million Non-Dilutive Term Loan Financing GlobeNewswire
07:00AM  GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia GlobeNewswire
Dec-16-19 07:35AM  Hedge Funds Are Dumping Syros Pharmaceuticals, Inc. (SYRS) Insider Monkey
Dec-08-19 08:00AM  Syros Presents on Identification of Novel Fetal Hemoglobin Repressor as Part of Broader Drug Discovery Program in Sickle Cell Disease at 61st Annual ASH Meeting Business Wire
Dec-03-19 11:44PM  Edited Transcript of SYRS earnings conference call or presentation 12-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Dec-02-19 01:50PM  Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award PR Newswire -5.69%
Nov-26-19 08:31AM  Syros to Present at Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
08:31AM  Syros to Present at Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-19-19 07:01AM  Syros to Present on Core Drivers of Metastasis in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium Business Wire
Nov-12-19 09:25AM  Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:00AM  Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones Business Wire
Nov-06-19 06:09PM  Were Hedge Funds Right About Snapping Up Syros Pharmaceuticals, Inc. (SYRS)? Insider Monkey
09:01AM  Syros to Present on Sickle Cell Disease Research at 61st Annual ASH Meeting Business Wire
Nov-05-19 08:30AM  Syros to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 Business Wire
Oct-31-19 10:34AM  Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-29-19 04:01PM  Syros Presents New Preclinical Data on SY-5609, Its Highly Selective Oral CDK7 Inhibitor, at AACR-NCI-EORTC International Conference Business Wire
Oct-25-19 08:47AM  Syros Pharmaceuticals Enters Oversold Territory Zacks
Oct-24-19 08:31AM  Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients Business Wire
Oct-17-19 07:00AM  Syros Announces Update on Selective CDK7 Inhibitor Portfolio Business Wire -31.09%
Sep-20-19 02:55PM  Does Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Have A Volatile Share Price? Simply Wall St.
Sep-13-19 10:24AM  Syros Pharmaceuticals moving HQ out of East Cambridge American City Business Journals
Aug-27-19 01:59AM  Edited Transcript of SYRS earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-06-19 04:01PM  Syros to Present at 2019 Wedbush PacGrow Healthcare Conference Business Wire
Aug-02-19 10:24PM  Syros Pharmaceuticals, Inc.(SYRS) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 09:05AM  Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates Zacks +13.37%
Jul-25-19 08:30AM  Syros to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019 Business Wire
Jun-27-19 07:25AM  What Did Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Take Home Last Year? Simply Wall St. +10.42%
07:23AM  Does Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Pay Compare Well With Peers? Simply Wall St.
Jun-12-19 08:31AM  Syros Announces Appointment of Alice T. Shaw to its Board of Directors Business Wire +7.14%
08:01AM  Syros to Present at JMP Securities Life Sciences Conference Business Wire
May-07-19 08:31AM  New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers Business Wire -6.43%
May-06-19 09:17AM  Edited Transcript of SYRS earnings conference call or presentation 1-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-02-19 07:59AM  What Are Analysts Expecting From Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Over The Next Few Years? Simply Wall St.
May-01-19 11:24PM  Syros Pharmaceuticals, Inc.(SYRS) Q1 2019 Earnings Call Transcript Motley Fool
08:55AM  Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:30AM  Syros Reports First Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones Business Wire
Apr-24-19 08:01AM  Syros to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019 Business Wire
Apr-17-19 08:01AM  Syros to Host Key Opinion Leader Symposium on CDK7 Inhibition on April 24, 2019 Business Wire
Apr-09-19 04:01PM  Syros Announces Closing of Concurrent Public Offerings Business Wire -7.84%
Apr-05-19 01:41PM  Here's Why Syros Pharmaceuticals Is Collapsing Today Motley Fool -23.28%
07:48AM  The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership Benzinga
07:15AM  Syros Announces Pricing of $70 Million Concurrent Public Offerings Business Wire
Apr-04-19 04:18PM  Syros Announces Proposed Concurrent Public Offerings of Common Stock with Warrants to Purchase Common Stock and Preferred Stock with Warrants to Purchase Common Stock Business Wire
Apr-02-19 04:01PM  Syros Presents New Preclinical Data on SY-1365 and SY-5609 at AACR Annual Meeting Business Wire
Mar-13-19 02:03AM  Edited Transcript of SYRS earnings conference call or presentation 7-Mar-19 1:30pm GMT Thomson Reuters StreetEvents +10.82%
Mar-12-19 02:17PM  Did You Manage To Avoid Syros Pharmaceuticalss (NASDAQ:SYRS) 47% Share Price Drop? Simply Wall St. +10.94%
Mar-07-19 12:50PM  Syros Pharmaceuticals, Inc. (SYRS) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:30AM  Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs Business Wire
Mar-06-19 08:31AM  Syros to Participate in Upcoming Investor Conferences in March Business Wire
Feb-28-19 08:30AM  Syros to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 7, 2019 Business Wire
Feb-27-19 04:31PM  Syros to Present New Preclinical Data on Its Selective CDK7 Inhibitors, SY-1365 and SY-5609, at AACR Annual Meeting Business Wire +5.33%
Feb-05-19 08:20AM  Analysis: Positioning to Benefit within ArcBest, International Game Technology, eHealth, Syros Pharmaceuticals, La Jolla Pharmaceutical, and Virtus Investment Partners Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-06-19 05:00PM  Syros Announces Strategic Priorities and Expected Milestones Business Wire
Jan-03-19 08:01AM  Syros to Present at 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-21-18 08:01AM  Syros Added to NASDAQ Biotechnology Index Business Wire
Dec-07-18 08:01AM  Syros Announces New Preclinical Data on SY-1365 at San Antonio Breast Cancer Symposium Business Wire
Dec-02-18 12:01PM  Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting Business Wire
Nov-30-18 08:30AM  Market Trends Toward New Normal in Gartner, CONVERGEONE HLD, Syros Pharmaceuticals, Akers Biosciences, Edge Therapeutics, and Cracker Barrel Old Country Store Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-20-18 08:01AM  Syros to Present at 30th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-15-18 09:30AM  Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors Business Wire +5.33%
Nov-13-18 07:01AM  Syros Presents New Preclinical Combination Data on SY-1365 and First Preclinical Data from Oral CDK7 Inhibitor Program at EORTC-NCI-AACR Meeting Business Wire
Nov-09-18 04:01PM  Syros Announces Presentation of New Preclinical Data on SY-1365 in Treatment-Resistant HR-Positive Breast Cancer Cell Lines at San Antonio Breast Cancer Symposium Business Wire
Nov-07-18 03:30PM  Edited Transcript of SYRS earnings conference call or presentation 1-Nov-18 11:30am GMT Thomson Reuters StreetEvents
Nov-01-18 09:01AM  Syros to Present Initial Clinical Data from Combination Cohorts in Its Ongoing Phase 2 Trial of SY-1425 at ASH Annual Meeting Business Wire +12.61%
07:00AM  Syros Reports Third Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones Business Wire
Oct-30-18 07:01AM  Syros to Present Clinical and Preclinical Data on SY-1365 and Earlier-Stage Pipeline at EORTC-NCI-AACR Meeting Business Wire
Oct-25-18 07:30AM  Syros to Report Third Quarter 2018 Financial Results on Thursday, November 1, 2018 Business Wire +9.41%
Oct-23-18 08:50AM  Market Trends Toward New Normal in Syros Pharmaceuticals, Westlake Chemical Partners LP, SITO Mobile, ShotSpotter, Motorcar Parts of America, and Benefitfocus Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Sep-28-18 03:41PM  Who Are The Major Shareholders Of Syros Pharmaceuticals Inc (NASDAQ:SYRS)? Simply Wall St.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Young Richard ADirectorMay 15Sale9.225,99055,242365,151May 15 05:13 PM
Alles Mark JDirectorMay 13Buy8.8610,00088,59010,000May 13 05:05 PM
Young Richard ADirectorApr 15Sale8.7523,960209,650371,141Apr 17 04:02 PM
Olson Eric RChief Scientific OfficerFeb 18Sale7.381,44610,6740Feb 20 04:15 PM
Simonian Nancy APresident & CEODec 23Option Exercise3.0452,401159,299533,689Dec 23 04:54 PM
Springhorn Jeremy P.Chief Business OfficerNov 12Buy4.9710,12150,26835,000Nov 12 04:34 PM
Springhorn Jeremy P.Chief Business OfficerNov 11Buy4.999,87949,32824,879Nov 12 04:34 PM